Sophiris Bio Inc. (NASDAQ:SPHS) Files An 8-K Results of Operations and Financial Condition
Item 2.02 have been furnished and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to liability
under that section nor shall they be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing regardless of any
general incorporation language.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
99.1 Press release dated May 15, 2017.
About Sophiris Bio Inc. (NASDAQ:SPHS)
Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer. Sophiris Bio Inc. (NASDAQ:SPHS) Recent Trading Information
Sophiris Bio Inc. (NASDAQ:SPHS) closed its last trading session down -0.06 at 2.59 with 852,623 shares trading hands.
